These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 27094761)

  • 1. Characterization of a sensitive mouse Aβ40 PD biomarker assay for Alzheimer's disease drug development in wild-type mice.
    Lu Y; Hoyte K; Montgomery WH; Luk W; He D; Meilandt WJ; Zuchero YJ; Atwal JK; Scearce-Levie K; Watts RJ; DeForge LE
    Bioanalysis; 2016 May; 8(10):1067-75. PubMed ID: 27094761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.
    Yu YJ; Atwal JK; Zhang Y; Tong RK; Wildsmith KR; Tan C; Bien-Ly N; Hersom M; Maloney JA; Meilandt WJ; Bumbaca D; Gadkar K; Hoyte K; Luk W; Lu Y; Ernst JA; Scearce-Levie K; Couch JA; Dennis MS; Watts RJ
    Sci Transl Med; 2014 Nov; 6(261):261ra154. PubMed ID: 25378646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model.
    Durairajan SS; Liu LF; Lu JH; Chen LL; Yuan Q; Chung SK; Huang L; Li XS; Huang JD; Li M
    Neurobiol Aging; 2012 Dec; 33(12):2903-19. PubMed ID: 22459600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
    Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U
    J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for Abeta production inhibitors.
    El Mouedden M; Vandermeeren M; Meert T; Mercken M
    Curr Pharm Des; 2006; 12(6):671-6. PubMed ID: 16472156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide.
    Sumbria RK; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    Mol Pharm; 2013 Sep; 10(9):3507-13. PubMed ID: 23924247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulation of AβPP processing alleviates amyloid-β-related pathology in Alzheimer's disease transgenic mice.
    Arbel-Ornath M; Becker M; Rabinovich-Toidman P; Gartner M; Solomon B
    J Alzheimers Dis; 2010; 22(2):469-82. PubMed ID: 20847413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular markers of Alzheimer disease early diagnostic: investigation perspectives of peripheral tissues.].
    Paltsev MA; Zuev VA; Kozhevnikova EO; Linkova NS; Kvetnaia TV; Polyakova VO; Kvetnoy IM
    Adv Gerontol; 2017; 30(6):809-817. PubMed ID: 29608821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
    Ohno M; Chang L; Tseng W; Oakley H; Citron M; Klein WL; Vassar R; Disterhoft JF
    Eur J Neurosci; 2006 Jan; 23(1):251-60. PubMed ID: 16420434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
    Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
    J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
    Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
    J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Camelid heavy chain only antibody fragment domain against β-site of amyloid precursor protein cleaving enzyme 1 inhibits β-secretase activity in vitro and in vivo.
    Dorresteijn B; Rotman M; Faber D; Schravesande R; Suidgeest E; van der Weerd L; van der Maarel SM; Verrips CT; El Khattabi M
    FEBS J; 2015 Sep; 282(18):3618-31. PubMed ID: 26147692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
    Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
    Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the brain and plasma Aβ peptide levels with age and its relationship with cognitive impairment in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Izco M; Martínez P; Corrales A; Fandos N; García S; Insua D; Montañes M; Pérez-Grijalba V; Rueda N; Vidal V; Martínez-Cué C; Pesini P; Sarasa M
    Neuroscience; 2014 Mar; 263():269-79. PubMed ID: 24447596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations of amyloid-β concentrations between CSF and plasma in acute Alzheimer mouse model.
    Cho SM; Kim HV; Lee S; Kim HY; Kim W; Kim TS; Kim DJ; Kim Y
    Sci Rep; 2014 Oct; 4():6777. PubMed ID: 25345439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
    Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
    J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.
    Nishitomi K; Sakaguchi G; Horikoshi Y; Gray AJ; Maeda M; Hirata-Fukae C; Becker AG; Hosono M; Sakaguchi I; Minami SS; Nakajima Y; Li HF; Takeyama C; Kihara T; Ota A; Wong PC; Aisen PS; Kato A; Kinoshita N; Matsuoka Y
    J Neurochem; 2006 Dec; 99(6):1555-63. PubMed ID: 17083447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
    Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
    J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triptolide treatment reduces Alzheimer's disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD.
    Wang Q; Xiao B; Cui S; Song H; Qian Y; Dong L; An H; Cui Y; Zhang W; He Y; Zhang J; Yang J; Zhang F; Hu G; Gong X; Yan Z; Zheng Y; Wang X
    Dis Model Mech; 2014 Dec; 7(12):1385-95. PubMed ID: 25481013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.